ClinicalTrials.gg
Status unknownNCT01771432BAC01Updated Jun 22, 2015

Antibiotic Treatment Versus no Therapy in Kidney Transplant Recipients With Asymptomatic Bacteriuria

An interventional study of Antibiotic treatment and No treatment in Asymptomatic Bacteriuria and Pyelonephritis, sponsored by Núria Sabé Fernàndez. Status unknown at 2 sites in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-06-22.

Sponsored by Núria Sabé Fernàndez · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jun 2015), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Objective: To determine whether antibiotic treatment of asymptomatic bacteriuria in kidney transplant recipients could be useful to prevent pyelonephritis in these patients.

Read the detailed description

Design: Randomized prospective study. Setting: University Hospital with an active kidney transplantation program. Patients: Adult kidney transplant recipients. Interventions: Kidney transplant recipients with asymptomatic bacteriuria will be randomly assigned to be treated with antibiotics or to be followed without antibiotic therapy.

Measurements: Urine cultures will be collected weekly during the first month after transplantation, every 2 weeks until three months after transplantation, every month until 6 months after transplantation and every 3 months until 12 months after transplantation. Urine culture will be as well collected if urinary symptoms appeared.

Primary end points: To determine in both groups: the incidence of pyelonephritis.

Secondary end points: To determine outcomes in both groups (renal function, hospitalization, rejection, graft loss, opportunistic infections and mortality) and infection by multiresistant microorganisms.

02

Conditions studied

  • Asymptomatic Bacteriuria
  • Pyelonephritis

Browse trials for

03

In context

Pyelonephritis

79 studies on the registry are indexed under Pyelonephritis; 12 are open to participants now.

This study's planned enrollment of 200 is above the median of 175 across 62 interventional studies indexed under Pyelonephritis.

Browse Pyelonephritis studies →

Lead sponsor

This is the only study on the registry with Núria Sabé Fernàndez as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who receive a transplant allograft during study period

Exclusion criteria

Exclusion Criteria:

  • No acceptation of study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Antibiotic treatment

    Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics.

    Drug: Antibiotic treatment

  • Other
    No treatment

    Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy

    Other: No treatment

Interventions

  • DrugAntibiotic treatment

    Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics

  • OtherNo treatment

    Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy

06

What researchers measure

Primary outcomes

  1. To determine the incidence of pyelonephritis in both groups

    Time frame: First year after kidney transplantation

Secondary outcomes

  1. Renal function

    Time frame: First year after kydney transplantation

  2. Need for hospitalization

    Time frame: First year after kydney transplantation

  3. Incidence of graft loss

    Time frame: First year after kidney transplantation

  4. Mortality

    Time frame: First year after kidney transplantation

Other outcomes

  1. Infection by multiresistant microorganisms

    Time frame: First year after kydney transplantation

07

Study locations

2 of 2 sites recruiting
  • Hospital Universitari de Bellvitge
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
    Recruiting
  • Hospital Vall d'Hebron
    Barcelona, Spain
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Sep 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2012
First posted
Jan 18, 2013
Start
Jan 2013
Primary completionEst.
Sep 2015
CompletionEst.
Dec 2015
Last update
Jun 22, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01771432
Lead sponsor
Núria Sabé Fernàndez
Responsible party
Núria Sabé Fernàndez (Infectious Diseases Phisycian, Hospital Universitari de Bellvitge) — Sponsor-investigator
First posted
Jan 18, 2013
Start date
Jan 2013
Primary completion
Sep 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
Jun 22, 2015

Study contacts

Núria Sabé Fernàndez
Contact
nfsabe@bellvitgehospital.cat
+932607625
Núria Sabé Fernàndez
principal investigator · Hospital Universitari de Bellvitge

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion